Which medications are used in the treatment of Lambert-Eaton myasthenic syndrome (LEMS)?

Updated: May 23, 2019
  • Author: David E Stickler, MD; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
  • Print

Limited data from randomized controlled trials examining different interventions for LEMS are available. A Cochrane review identified only 4 controlled trials of 3,4-diaminopyridine (DAP) and a single cross-over study that examined the use of IV immunoglobulin (IVIg) and concluded that there was limited but moderate-to-high-quality evidence to suggest improved muscle strength with these interventions. [7] All other potential interventions have not been examined in controlled trials.

Recent studies have introduced a Ca2+ channel agonist (GV-58) as a potential therapeutic alternative for LEMS. In addition, in a mouse model, GV-58 and 3,4-DAP were shown to interact in a supra-additive manner to restore the magnitude of neurotransmitter release at the neuromuscular junctions. [2, 11]

The initial pharmacotherapy for LEMS is with agents that increase the transmission of acetylcholine (ACh) across the neuromuscular junction, either by increasing the release of ACh (eg, DAP [12] ) or by decreasing the action of acetylcholinesterase (eg, pyridostigmine). Treatment of the associated cancer may also decrease the weakness and other symptoms.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!